Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free APS Stock Alerts

Aptose Biosciences (APS) Competitors

Aptose Biosciences logo
C$2.28 -0.10 (-4.20%)
As of 05/25/2026 09:30 AM Eastern
Compare

APS vs. LTY, ACST, REUN, NEPT, and ATE

Should you buy Aptose Biosciences stock or one of its competitors? MarketBeat compares Aptose Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptose Biosciences include Liberty Biopharma (LTY), Acasti Pharma (ACST), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), and Antibe Therapeutics (ATE). These companies are all part of the "biotechnology" industry.

How does Aptose Biosciences compare to Liberty Biopharma?

Aptose Biosciences (TSE:APS) and Liberty Biopharma (CVE:LTY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

In the previous week, Liberty Biopharma had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 1 mentions for Liberty Biopharma and 0 mentions for Aptose Biosciences. Liberty Biopharma's average media sentiment score of 0.67 beat Aptose Biosciences' score of 0.00 indicating that Liberty Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Aptose Biosciences Neutral
Liberty Biopharma Positive

Aptose Biosciences' return on equity of 115.24% beat Liberty Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A 115.24% -136.29%
Liberty Biopharma N/A N/A N/A

Liberty Biopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$154.69M-C$10.41N/A
Liberty BiopharmaN/AN/AN/A-C$0.16N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Liberty Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

0.0% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aptose Biosciences beats Liberty Biopharma on 5 of the 9 factors compared between the two stocks.

How does Aptose Biosciences compare to Acasti Pharma?

Acasti Pharma (CVE:ACST) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

0.1% of Acasti Pharma shares are owned by institutional investors. Comparatively, 0.0% of Aptose Biosciences shares are owned by institutional investors. 20.3% of Acasti Pharma shares are owned by insiders. Comparatively, 17.1% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Acasti Pharma's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company Overall Sentiment
Acasti Pharma Neutral
Aptose Biosciences Neutral

Acasti Pharma has higher revenue and earnings than Aptose Biosciences. Acasti Pharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acasti PharmaC$2.71M6.71-C$10.54M-C$0.48N/A
Aptose BiosciencesN/AN/A-C$154.69M-C$10.41N/A

Acasti Pharma has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Aptose Biosciences has a beta of -1.238347, meaning that its stock price is 224% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acasti Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aptose Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Aptose Biosciences has a net margin of 0.00% compared to Acasti Pharma's net margin of -455.58%. Aptose Biosciences' return on equity of 115.24% beat Acasti Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Acasti Pharma-455.58% -67.58% -8.25%
Aptose Biosciences N/A 115.24%-136.29%

Summary

Acasti Pharma beats Aptose Biosciences on 7 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Reunion Neuroscience?

Aptose Biosciences (TSE:APS) and Reunion Neuroscience (TSE:REUN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

0.0% of Aptose Biosciences shares are held by institutional investors. Comparatively, 50.7% of Reunion Neuroscience shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Comparatively, 34.4% of Reunion Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Given Reunion Neuroscience's higher possible upside, analysts clearly believe Reunion Neuroscience is more favorable than Aptose Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Reunion Neuroscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Reunion Neuroscience'saverage media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
Reunion Neuroscience Neutral

Aptose Biosciences has a beta of -1.238347, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Reunion Neuroscience has a beta of 4.2, meaning that its stock price is 320% more volatile than the broader market.

Reunion Neuroscience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Reunion Neuroscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$154.69M-C$10.41N/A
Reunion NeuroscienceC$4.86M0.00-C$38.10M-C$3.30N/A

Aptose Biosciences' return on equity of 115.24% beat Reunion Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A 115.24% -136.29%
Reunion Neuroscience N/A -86.35%-26.50%

Summary

Reunion Neuroscience beats Aptose Biosciences on 8 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Aptose Biosciences (TSE:APS) and Neptune Wellness Solutions (TSE:NEPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Aptose Biosciences' return on equity of 115.24% beat Neptune Wellness Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A 115.24% -136.29%
Neptune Wellness Solutions N/A N/A N/A

0.0% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aptose Biosciences has higher earnings, but lower revenue than Neptune Wellness Solutions. Aptose Biosciences is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$154.69M-C$10.41N/A
Neptune Wellness SolutionsC$48.80M0.00-C$192.95M-C$24.16N/A

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Neptune Wellness Solutions'average media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
Neptune Wellness Solutions Neutral

Given Neptune Wellness Solutions' higher probable upside, analysts plainly believe Neptune Wellness Solutions is more favorable than Aptose Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Neptune Wellness Solutions
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aptose Biosciences beats Neptune Wellness Solutions on 6 of the 10 factors compared between the two stocks.

How does Aptose Biosciences compare to Antibe Therapeutics?

Aptose Biosciences (TSE:APS) and Antibe Therapeutics (TSE:ATE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

0.0% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by insiders. Comparatively, 7.9% of Antibe Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aptose Biosciences' return on equity of 115.24% beat Antibe Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A 115.24% -136.29%
Antibe Therapeutics N/A -52.72%-19.13%

Given Antibe Therapeutics' higher possible upside, analysts clearly believe Antibe Therapeutics is more favorable than Aptose Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Antibe Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Antibe Therapeutics has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$154.69M-C$10.41N/A
Antibe TherapeuticsC$9.71M0.00-C$18.24M-C$0.35N/A

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Antibe Therapeutics'average media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
Antibe Therapeutics Neutral

Aptose Biosciences has a beta of -1.238347, suggesting that its share price is 224% less volatile than the broader market. Comparatively, Antibe Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Summary

Antibe Therapeutics beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APS vs. The Competition

Export
MetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$5.82MC$477.13MC$6.46BC$12.16B
Dividend Yield0.39%3.87%2.76%6.20%
P/E Ratio-0.223.8121.2237.64
Price / SalesN/A7,288.62553.9211.68
Price / Cash1.6013.1343.4982.29
Price / Book-0.1784.7810.374.50
Net Income-C$154.69M-C$96.07MC$3.57BC$299.09M
7 Day Performance-2.15%0.04%6.40%2.48%
1 Month Performance-2.98%0.56%3.52%1.47%
1 Year Performance-8.43%63.39%34.02%53.55%

Aptose Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APS
Aptose Biosciences
N/AC$2.28
-4.2%		N/A-3.4%C$6.07MN/AN/A31
LTY
Liberty Biopharma
N/AC$2.00
+∞		N/A+0.0%C$21.54MN/AN/AN/A
ACST
Acasti Pharma
N/AC$0.58
+1.8%		N/A+0.0%C$18.19MC$2.71MN/A32
REUN
Reunion Neuroscience
N/AN/AN/AN/AC$16.64MC$4.86MN/A190
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AC$15.73MC$48.80MN/A130

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:APS) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel